抗体偶联药物作用机制示意图[4] - 上下滑动查看参考资料 - [1]Cao W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021, 134(7):783-791. [2]Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014: 852748. [3]Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the 'biological missile' for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. [4]唐煜,王相阳,马晓慧等. 抗体偶联药物内吞作用机制的研究进展. 中国新药杂志,2017,26(10):1130 [5]中国临床肿瘤学会乳腺癌诊疗指南2022版
|
|